Literature DB >> 25999449

Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.

Sanam Loghavi1, Naveen Pemmaraju1, Rashmi Kanagal-Shamanna1, Meenakshi Mehrotra1, L Jeffrey Medeiros1, Raja Luthra1, Pei Lin1, Yang Huh1, Hagop M Kantarjian2, Jorge E Cortes2, Srdan Verstovsek2, Keyur P Patel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25999449     DOI： 10.1182/blood-2015-03-632893

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  7 in total

Review 1.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

2.  CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.

Authors:  Irene Dogliotti; Carmen Fava; Anna Serra; Enrico Gottardi; Filomena Daraio; Francesca Carnuccio; Emilia Giugliano; Monica Bocchia; Giuseppe Saglio; Giovanna Rege-Cambrin
Journal:  Stem Cell Investig       Date:  2017-06-23

3.  Imatinib Treatment of Chronic Myeloid Leukemia Reveals a Preexisting CALR-mutated Essential Thrombocythemia.

Authors:  Anaïse Blouet; Marie-Christine Rousselet; Yannick Le Bris; Bénédicte Ribourtout; Anne Bouvier; Laurane Cottin; Rébecca Jouanneau-Courville; Odile Blanchet; Valérie Ugo; Damien Luque Paz
Journal:  Hemasphere       Date:  2018-02-05

Review 4.  Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review.

Authors:  Chunshui Liu; Ruiping Hu; Zhonghua Du; Manuel Abecasis; Cong Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

5.  Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm.

Authors:  Stephen E Langabeer
Journal:  EXCLI J       Date:  2020-01-08       Impact factor: 4.068

6.  Diagnostic and therapeutic implications of genetic heterogeneity in myeloid neoplasms uncovered by comprehensive mutational analysis.

Authors:  Sarah M Choi; Ben Goldenson; Lo Ann Peterson; Shira Dinner; Brady L Stein; Amir Behdad
Journal:  Leuk Res Rep       Date:  2017-09-20

Review 7.  Philadelphia+ Chronic Myeloid Leukemia with CALR Mutation: A Case Report and Literature Review.

Authors:  Seug Yun Yoon; Sun Young Jeong; Changgon Kim; Min-Young Lee; Jieun Kim; Kyoung-Ha Kim; Namsu Lee; Jong-Ho Won
Journal:  Cancer Res Treat       Date:  2020-01-15       Impact factor: 4.679
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.